Your browser is no longer supported. Please, upgrade your browser.
GNPX Genprex, Inc. daily Stock Chart
Genprex, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own23.00% Shs Outstand27.95M Perf Week2.64%
Market Cap102.51M Forward P/E12.44 EPS next Y0.25 Insider Trans0.00% Shs Float25.30M Perf Month-1.58%
Income-14.10M PEG- EPS next Q-0.07 Inst Own8.20% Short Float15.98% Perf Quarter43.32%
Sales- P/S- EPS this Y26.00% Inst Trans0.04% Short Ratio1.48 Perf Half Y814.71%
Book/sh0.86 P/B3.62 EPS next Y225.00% ROA-146.10% Target Price- Perf Year193.40%
Cash/sh0.70 P/C4.44 EPS next 5Y- ROE-157.00% 52W Range0.23 - 7.03 Perf YTD871.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.76% Beta-
Dividend %- Quick Ratio33.20 Sales past 5Y- Gross Margin- 52W Low1246.32% ATR0.24
Employees8 Current Ratio34.50 Sales Q/Q- Oper. Margin- RSI (14)47.80 Volatility5.86% 7.75%
OptionableYes Debt/Eq0.00 EPS Q/Q-41.50% Profit Margin- Rel Volume0.26 Prev Close3.12
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.73M Price3.11
Recom2.00 SMA200.42% SMA502.47% SMA20068.38% Volume696,454 Change-0.32%
Apr-29-19Initiated Noble Capital Markets Outperform $5
Jun-29-20 08:16AM  
Jun-25-20 08:17AM  
Jun-24-20 08:16AM  
Jun-16-20 08:17AM  
Jun-09-20 08:17AM  
Jun-08-20 08:17AM  
May-28-20 08:17AM  
May-05-20 01:00PM  
May-04-20 08:17AM  
Apr-21-20 08:17AM  
Mar-24-20 08:17AM  
Mar-23-20 08:17AM  
Mar-05-20 08:05AM  
Mar-04-20 08:00AM  
Mar-03-20 08:17AM  
Feb-21-20 04:15PM  
Feb-20-20 10:22AM  
Feb-19-20 09:23AM  
Feb-11-20 08:17AM  
Feb-06-20 08:17AM  
Feb-05-20 09:00AM  
Feb-03-20 08:17AM  
Jan-29-20 08:18AM  
Jan-28-20 08:00AM  
Jan-24-20 07:00AM  
Jan-23-20 09:00AM  
Jan-22-20 10:54AM  
Jan-21-20 08:00AM  
Jan-06-20 08:00AM  
Nov-20-19 11:15AM  
Nov-19-19 08:00AM  
Nov-04-19 08:00AM  
Oct-15-19 08:00AM  
Oct-09-19 08:00AM  
Oct-07-19 08:00AM  
Sep-26-19 08:30AM  
Sep-25-19 08:30AM  
Sep-18-19 08:00AM  
Sep-11-19 08:00AM  
Sep-07-19 04:35PM  
Sep-06-19 08:30AM  
Sep-04-19 01:43PM  
Aug-23-19 08:30AM  
Aug-22-19 08:30AM  
Aug-21-19 03:31PM  
Aug-13-19 08:00AM  
Aug-06-19 08:00AM  
Jul-31-19 08:30AM  
Jul-09-19 01:58PM  
Jul-01-19 08:30AM  
May-31-19 08:30AM  
May-30-19 08:35AM  
May-21-19 08:30AM  
May-09-19 08:30AM  
May-08-19 08:30AM  
Apr-12-19 09:00AM  
Apr-11-19 08:30AM  
Apr-08-19 08:30AM  
Apr-01-19 08:30AM  
Mar-29-19 09:00AM  
Mar-28-19 08:30AM  
Mar-19-19 08:30AM  
Mar-15-19 09:00AM  
Mar-14-19 08:30AM  
Mar-13-19 05:31PM  
Feb-27-19 08:30AM  
Feb-19-19 08:30AM  
Jan-23-19 08:30AM  
Jan-03-19 08:30AM  
Dec-25-18 01:14PM  
Dec-12-18 08:30AM  
Dec-03-18 08:30AM  
Nov-20-18 08:30AM  
Oct-30-18 08:00AM  
Oct-01-18 08:00AM  
Sep-27-18 08:00AM  
Aug-21-18 08:30AM  
Aug-15-18 08:30AM  
Aug-02-18 08:30AM  
Jul-26-18 08:30AM  
Jul-18-18 04:17PM  
Jul-02-18 09:30AM  
Jun-26-18 08:00AM  
May-31-18 08:30AM  
May-29-18 08:30AM  
May-23-18 10:55AM  
May-08-18 08:00AM  
May-07-18 08:05AM  
Apr-27-18 08:20AM  
Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.